Last reviewed · How we verify

NCT04818502: RESOLVE-MR

Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Active, enrolled Last updated 12 June 2024
What this trial tests

trial testing Tendyne™ Mitral Valve System in Mitral Valve Regurgitation in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
4 May 2021
Primary endpoint
31 May 2025
31 May 2029

Quick facts

Lead sponsorAbbott Medical Devices
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment200
Start date4 May 2021
Primary completion31 May 2025
Estimated completion31 May 2029
Sites36 locations across France, Italy, Netherlands, Belgium, Austria, Saudi Arabia, United Kingdom, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Abbott Medical Devices — full company profile →

Who can join

18 and older, any sex, with Mitral Valve Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and performance of the Tendyne™ Mitral Valve System when used as intended in a contemporary, real-world setting.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Transcatheter Mitral Valve Replacement Using Transcatheter Aortic Valve or Dedicated Devices: Current Evidence and Future Prospects.
    Quentin V, Mesnier J, Delhomme C, Sayah N, et al · · 2023 · cited 8× · PMID 37959178 · DOI 10.3390/jcm12216712

Verify or expand the search:

Other recruiting trials for Mitral Valve Regurgitation

Currently open trials in the same condition.

Other Abbott Medical Devices trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04818502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing